Compare CARG & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CARG | RNA |
|---|---|---|
| Founded | 2005 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 4.0B |
| IPO Year | 2017 | 2020 |
| Metric | CARG | RNA |
|---|---|---|
| Price | $38.46 | $72.25 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 20 |
| Target Price | $40.91 | ★ $69.26 |
| AVG Volume (30 Days) | 851.0K | ★ 2.3M |
| Earning Date | 02-19-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.46 | N/A |
| Revenue | ★ $926,425,000.00 | $20,868,000.00 |
| Revenue This Year | $6.83 | $57.30 |
| Revenue Next Year | $6.12 | $28.41 |
| P/E Ratio | $25.91 | ★ N/A |
| Revenue Growth | 4.21 | ★ 106.27 |
| 52 Week Low | $24.65 | $21.51 |
| 52 Week High | $41.33 | $72.61 |
| Indicator | CARG | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 59.24 | 72.40 |
| Support Level | $37.36 | $72.04 |
| Resistance Level | $38.79 | $72.20 |
| Average True Range (ATR) | 0.76 | 0.22 |
| MACD | -0.14 | -0.28 |
| Stochastic Oscillator | 53.79 | 57.56 |
CarGurus Inc is a company that acts as an online automotive marketplace connecting buyers and sellers of new and used cars. The company provides three types of marketplace Listing products, Restricted Listings, and Enhanced or Featured Listings, through which it offers real-time and historical data analyzing the connections and pricing analysis. The listing platforms offer auto manufacturers and others to buy advertising on the company's site and target consumers based on the make, model, and zip code of the cars. The company operates through two segments, namely U.S. Marketplace and Digital Wholesale. It generates maximum revenue from the U.S. Marketplace segment. Geographically, the company derives its key revenue from the United States and the rest from international markets.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.